BioGend Therapeutics Co., Ltd. (TPEX: 6733)

BioGend Therapeutics Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	133.87	330.51	163.64	136.32	120.04	89.77
Short-Term Investments	500	393.76	329.76	552.96	392.99	280
Cash & Short-Term Investments	633.87	724.27	493.4	689.28	513.03	369.77
Cash Growth	-15.57%	46.79%	-28.42%	34.36%	38.74%	-15.99%
Accounts Receivable	41.16	26.69	11.27	5.05	0.28	0.31
Other Receivables	31.56	30.67	28.25	23.61	21.62	0.6
Receivables	72.72	57.36	39.52	28.66	21.89	0.91
Inventory	15.05	16.55	4.9	9.03	10.41	2.51
Prepaid Expenses	3.27	3	4.07	7.57	1.42	22.08
Total Current Assets	724.91	801.18	541.89	734.54	546.75	395.27
Property, Plant & Equipment	51.58	56.2	34.01	8.89	5.94	8.74
Long-Term Investments	19.17	20.34	10	-	69.43	83.66
Goodwill	17.09	17.09	17.09	17.09	-	-
Other Intangible Assets	122.72	151.04	210.95	261.92	102.29	118.97
Other Long-Term Assets	5.89	4.64	7.89	1.42	0.94	0.62
Total Assets	941.35	1,050	821.82	1,024	725.34	607.26
Accounts Payable	2.85	2.16	2.08	0.49	1.36	1.07
Accrued Expenses	18.01	25.22	17.22	14.39	14.19	11.96
Current Portion of Leases	3.72	3.65	3.49	3.94	-	-
Other Current Liabilities	4.03	15.22	9.07	6.3	2.72	2.47
Total Current Liabilities	28.62	46.25	31.86	25.13	18.27	15.49
Long-Term Leases	6.65	9.44	12.28	0.48	-	-
Long-Term Unearned Revenue	-	2.5	2.5	2.5	2.5	2.5
Long-Term Deferred Tax Liabilities	29.23	35.52	43.92	52.31	-	-
Total Liabilities	64.5	93.71	90.56	80.42	20.77	17.99
Common Stock	1,243	1,231	1,031	1,031	920	820
Additional Paid-In Capital	-	-	-	212.85	160.9	301.11
Retained Earnings	-359.07	-281.85	-325.52	-353.91	-376.33	-531.84
Comprehensive Income & Other	-6.48	-7.96	-2.38	-2.16	-	-
Total Common Equity	877.01	940.96	702.86	887.54	704.57	589.26
Minority Interest	-0.16	15.81	28.4	55.91	-	-
Shareholders' Equity	876.85	956.77	731.27	943.45	704.57	589.26
Total Liabilities & Equity	941.35	1,050	821.82	1,024	725.34	607.26
Total Debt	10.37	13.09	15.77	4.42	-	-
Net Cash (Debt)	623.5	711.18	477.64	684.86	513.03	369.77
Net Cash Growth	-15.48%	48.90%	-30.26%	33.49%	38.74%	-15.99%
Net Cash Per Share	5.07	5.91	4.63	6.76	5.87	4.55
Filing Date Shares Outstanding	124.26	123.08	103.08	103.08	92	82
Total Common Shares Outstanding	124.26	123.08	103.08	103.08	92	82
Working Capital	696.3	754.93	510.03	709.42	528.47	379.78
Book Value Per Share	7.06	7.65	6.82	8.61	7.66	7.19
Tangible Book Value	737.2	772.83	474.82	608.52	602.28	470.3
Tangible Book Value Per Share	5.93	6.28	4.61	5.90	6.55	5.74
Machinery	31.6	31.19	24.66	24.55	23.87	24.67
Construction In Progress	-	37.57	14.91	-	-	-
Leasehold Improvements	37.91	0.34	0.34	0.34	3.03	3.03

Source: S&P Capital IQ. Standard template. Financial Sources.